LBRX - NASDAQ
LB Pharmaceuticals Inc Common Stock
$27.95
+3.4%Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.
At a Glance
Live Snapshotlbrx
Change in Working Capital
Last Annual Value
-13.65M
3-Year CAGR
-443%
5-Year CAGR
-176%
10-Year CAGR
-66%
LB Pharmaceuticals Inc Common Stock Competitors Analysis of Change in Working Capital
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX | -13.65M | N/A | N/A | N/A | |
 Aura Biosciences, Inc. NASDAQ:AURA | 5.97M | 10.4% | N/A | N/A | |
 Annexon, Inc. NASDAQ:ANNX | 4.23M | N/A | 5.2% | N/A | |
 Editas Medicine, Inc. NASDAQ:EDIT | -31.23M | N/A | N/A | N/A | |
 Humacyte, Inc. NASDAQ:HUMA | -23.39M | N/A | N/A | N/A | |
 Kyverna Therapeutics, Inc. NASDAQ:KYTX | -1.08M | N/A | N/A | N/A | |
 Lyell Immunopharma, Inc. NASDAQ:LYEL | -9.89M | N/A | N/A | N/A | |
 Replimune Group, Inc. NASDAQ:REPL | 24.08M | 16.8% | 47.0% | N/A | |
 Tenaya Therapeutics, Inc. NASDAQ:TNYA | -2.46M | N/A | N/A | N/A | |
 Rocket Pharmaceuticals, Inc. NASDAQ:RCKT | -8.30M | N/A | N/A | N/A | |
 Korro Bio, Inc. NASDAQ:KRRO | -4.43M | N/A | N/A | N/A |
LB Pharmaceuticals Inc Common Stock Fair Value Envelope
Related Guides
Continue your LBRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.